Phase II Trial of Pemetrexed and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer

PURPOSE: We hypothesized that bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), will potentiate the activity of pemetrexed, a multitargeted antifolate, in squamous cell carcinoma of the head and neck (SCCHN). PATIENTS AND METHODS: Patients with previously untreate...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Argiris, Athanassios, Karamouzis, Michalis V., Gooding, William E., Branstetter, Barton F., Zhong, Shilong, Raez, Luis E., Savvides, Panayiotis, Romkes, Marjorie
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2011
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3083869/
https://ncbi.nlm.nih.gov/pubmed/21343546
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.33.3591
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados